RSV remains a severe infection in infants and children. In this report, data on the activity of clesrovimab, a long-lasting RSV monoclonal antibody, are described as compared with palivizumab.
Clesrovimab in Infants and Children at Increased Risk for Severe RSV Disease
Manzoni, P;
2025-01-01
Abstract
RSV remains a severe infection in infants and children. In this report, data on the activity of clesrovimab, a long-lasting RSV monoclonal antibody, are described as compared with palivizumab.
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
NEJM 2025 - Multicenter Clesrovimab registration trial.pdf
Accesso aperto
Dimensione
312.27 kB
Formato
Adobe PDF
|
312.27 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
